Lyra Therapeutics Inc
NASDAQ:LYRA
Lyra Therapeutics Inc
NASDAQ:LYRA
Price:
0.3558 USD
-4.35%
Market Closed
Updated:
May 16, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
-39
Current
37.9
Median
2.6
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=-39
Enterprise Value
/
-65.4m
Revenue
1.7m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| US |
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
21.7m USD | -39 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
748B USD | 21.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.8 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
367.4B USD | 4.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
333.6B USD | 5.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.7B GBP | 50.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.5B CHF | 3.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
181.4B CHF | 3.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162.7B USD | 4 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
-46.5
2-Years Forward
EV/S
-82.1
3-Years Forward
EV/S
-2.1
You don't have any saved screeners yet
